Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glucagon Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Action in Physiology and Diabetes

NCT02550548
View directory record Official record
Conditions
Insulin Secretion
Interventions
GIP infusion, GLP-1 infusion, Ex-9 infusion
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 20, 2026, 12:44 AM EDT
Recruiting No phase listed Observational

The T1D Exchange Registry

NCT04629586
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes, Type 1 Diabetes, Diabetes Mellitus
Interventions
No intervention
Other
Lead sponsor
T1D Exchange, United States
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 20, 2026, 12:44 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

NCT01803451
View directory record Official record
Conditions
Post-bariatric Surgery
Interventions
exendin -(9-39)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes

NCT02081014
View directory record Official record
Conditions
Hypoglycemia
Interventions
G-Pen Mini™ (glucagon injection)
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 3 Interventional Results available

Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

NCT03091673
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
7
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

NCT04432090
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Study Medication (MBX-2982), No medication for this group
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 20, 2026, 12:44 AM EDT
Active, not recruiting No phase listed Observational

Comparison of Body Composition Changes With Weight Loss Interventions

NCT07115069
View directory record Official record
Conditions
Obesity
Interventions
GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic)
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Real-time Adaptation to Changes in Insulin Sensitivity

NCT01261052
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm, The Adaptive Proportional Derivative Algorithm
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 20, 2026, 12:44 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
View directory record Official record
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

NCT02625636
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR438544, placebo, r-glucagon
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Oct 20, 2026, 12:44 AM EDT
Recruiting Phase 2 Interventional

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

NCT07685808
View directory record Official record
Conditions
Overweight or Obesity
Interventions
Olatorepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Mobile, Alabama • Walnut Creek, California • Waterbury, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 12:44 AM EDT
Not yet recruiting Not applicable Interventional

High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

NCT07700030
View directory record Official record
Conditions
Weight Loss
Interventions
High protein diet, Resistance Training (RT) Programs
Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
30 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

NCT00013910
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
NNC 90-1170
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
30 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 12:44 AM EDT
Recruiting Phase 2 Interventional

GLP-1R Agonist Treatment for Opioid Use Disorder

NCT06548490
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

NCT01966978
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus

NCT00304538
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
very low dose (VLD) glucagon
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2006 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 4 Interventional

Once Weekly GLP-1 in Persons With Spinal Cord Injury

NCT03292315
View directory record Official record
Conditions
Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity
Interventions
Semaglutide 1MG Injection [Ozempic], No Intervention
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 69 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 20, 2026, 12:44 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging

NCT07216352
View directory record Official record
Conditions
Laxity; Skin
Interventions
AGE Serum
Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
25 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Not applicable Interventional

Breakfast Intake and Satiety Hormones

NCT02497859
View directory record Official record
Conditions
Obesity
Interventions
Egg Breakfast (EB), Cereal Breakfast (CB), Weight Loss Counseling, Weight Loss Diet
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants

NCT03859323
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SHP681, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 20, 2026, 12:44 AM EDT
Terminated Not applicable Interventional

Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation

NCT06273163
View directory record Official record
Conditions
Obesity
Interventions
Medically tailored meals, Noom®, Usual care
Other · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 20, 2026, 12:44 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

NCT07497880
View directory record Official record
Conditions
Obesity, Overweight
Interventions
KAI-7535, Placebo
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
31
States / cities
Chandler, Arizona • Phoenix, Arizona • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 12:44 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Assess Impact of Poly-L-lactic Acid on GLP1 Subjects

NCT07217743
View directory record Official record
Conditions
Laxity; Skin
Interventions
Sculptra Aesthetic
Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 20, 2026, 12:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Bethanechol on Glucose Homeostasis

NCT01434901
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 20, 2026, 12:44 AM EDT